See more : Nuheara Limited (NUH.AX) Income Statement Analysis – Financial Results
Complete financial analysis of SymBio Pharmaceuticals Limited (SYMQY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SymBio Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sagami Rubber Industries Co., Ltd. (5194.T) Income Statement Analysis – Financial Results
- Tatia Global Vennture Limited (TATIAGLOB.BO) Income Statement Analysis – Financial Results
- The Scottish American Investment Company P.L.C. (SAIN.L) Income Statement Analysis – Financial Results
- PT Pratama Widya Tbk (PTPW.JK) Income Statement Analysis – Financial Results
- Bridgetown 2 Holdings Limited (BTNB) Income Statement Analysis – Financial Results
SymBio Pharmaceuticals Limited (SYMQY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.symbiopharma.com
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.59B | 10.01B | 8.25B | 2.99B | 2.84B | 3.84B | 3.44B | 2.37B | 1.93B | 1.96B | 1.53B | 1.96B | 1.88B | 1.45B | 1.19B | 1.63B |
| Cost of Revenue | 1.18B | 2.41B | 2.45B | 2.12B | 1.97B | 2.66B | 2.41B | 1.46B | 1.35B | 1.43B | 1.21B | 1.36B | 1.22B | 238.18M | 0.00 | 0.00 |
| Gross Profit | 4.41B | 7.60B | 5.80B | 866.85M | 864.75M | 1.17B | 1.03B | 904.19M | 583.00M | 526.64M | 317.99M | 592.98M | 658.34M | 1.21B | 1.19B | 1.63B |
| Gross Profit Ratio | 78.91% | 75.94% | 70.28% | 29.02% | 30.47% | 30.58% | 29.94% | 38.18% | 30.16% | 26.94% | 20.76% | 30.33% | 34.97% | 83.57% | 100.00% | 100.00% |
| Research & Development | 2.64B | 2.55B | 1.74B | 2.27B | 2.44B | 1.83B | 3.02B | 1.67B | 2.03B | 774.10M | 1.05B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 130.00M | 122.00M | 1.34B | 524.43M | 5.17B | 3.83B | 4.98B | 3.03B | 3.13B | 1.83B | 2.00B | 2.29B | 2.73B | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 937.00M | 1.48B | 1.64B | 1.30B | 733.69M | 405.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.58B | 3.08B | 2.98B | 3.07B | 5.17B | 3.83B | 4.98B | 3.03B | 3.13B | 1.83B | 2.00B | 2.29B | 2.73B | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | -54.16M | 4.57M | -43.96M | -10.68M | -11.05M | -9.26M | -26.29M | -9.65M | -11.67M | -6.11M | -9.90M | -4.67M | -13.81M | -15.19M | -68.19M |
| Operating Expenses | 5.22B | 5.64B | 4.78B | 5.37B | 5.17B | 3.83B | 4.98B | 3.03B | 3.13B | 1.83B | 2.00B | 2.29B | 2.73B | 1.82B | 1.40B | 1.50B |
| Cost & Expenses | 6.40B | 8.04B | 7.24B | 7.49B | 7.14B | 6.49B | 7.39B | 4.50B | 4.48B | 3.26B | 3.21B | 3.66B | 3.95B | 2.06B | 1.40B | 1.50B |
| Interest Income | 11.00M | 98.00K | 125.00K | 257.00K | 311.00K | 641.00K | 3.09M | 5.48M | 16.27M | 24.85M | 10.03M | 4.94M | 3.42M | 3.43M | 7.71M | 5.98M |
| Interest Expense | 10.51M | 0.00 | 1.95M | 27.02M | 13.93M | 29.65M | 14.48M | 4.00K | 13.00K | 67.00K | 31.00K | 137.00K | 668.00K | 2.33M | 10.40M | 2.17M |
| Depreciation & Amortization | 96.01M | 98.09M | 93.96M | 63.84M | 38.09M | 34.70M | 29.57M | 25.65M | 24.24M | 12.66M | 8.16M | 8.56M | 8.17M | 6.52M | 4.34M | 4.30M |
| EBITDA | -715.66M | 2.06B | 1.11B | -4.44B | -4.26B | -2.62B | -3.92B | -2.10B | -2.53B | -1.29B | -1.67B | -1.72B | -2.09B | -606.27M | -203.69M | 137.16M |
| EBITDA Ratio | -12.80% | 19.54% | 13.45% | -166.45% | -150.49% | -68.34% | -113.82% | -96.75% | -134.81% | -56.14% | -103.99% | -88.01% | -110.84% | -41.26% | -17.10% | 8.47% |
| Operating Income | -811.67M | 1.96B | 1.02B | -4.51B | -4.30B | -2.66B | -3.95B | -2.13B | -2.55B | -1.30B | -1.68B | -1.70B | -2.07B | -612.79M | -208.03M | 132.86M |
| Operating Income Ratio | -14.52% | 19.62% | 12.31% | -150.86% | -151.59% | -69.25% | -114.60% | -89.82% | -131.99% | -66.66% | -109.69% | -86.96% | -109.79% | -42.26% | -17.46% | 8.15% |
| Total Other Income/Expenses | -383.72M | 142.65M | -14.67M | 419.80M | -70.84M | -92.66M | -27.00M | -182.38M | -76.63M | 191.20M | 79.10M | -29.25M | -33.87M | -25.71M | -6.05M | -109.58M |
| Income Before Tax | -1.20B | 2.11B | 1.00B | -4.09B | -4.37B | -2.75B | -3.97B | -2.31B | -2.63B | -1.11B | -1.60B | -1.73B | -2.10B | -638.51M | -214.07M | 23.28M |
| Income Before Tax Ratio | -21.39% | 21.05% | 12.13% | -136.80% | -154.08% | -71.67% | -115.38% | -97.52% | -135.95% | -56.88% | -104.53% | -88.46% | -111.59% | -44.04% | -17.97% | 1.43% |
| Income Tax Expense | 767.43M | 927.04M | -1.03B | 3.80M | 3.80M | 3.80M | 3.80M | 3.80M | 3.80M | 3.80M | 3.80M | 3.80M | 3.80M | 3.80M | 3.80M | 2.29M |
| Net Income | -1.96B | 1.18B | 2.03B | -4.09B | -4.38B | -2.75B | -3.98B | -2.31B | -2.63B | -1.12B | -1.61B | -1.73B | -2.10B | -642.31M | -217.87M | 20.99M |
| Net Income Ratio | -35.11% | 11.78% | 24.63% | -136.93% | -154.22% | -71.76% | -115.49% | -97.68% | -136.15% | -57.08% | -104.78% | -88.65% | -111.79% | -44.30% | -18.29% | 1.29% |
| EPS | -49.19 | 30.20 | 53.04 | -124.13 | -189.03 | -165.54 | -319.14 | -235.27 | -325.04 | -145.03 | -277.15 | -362.41 | -574.39 | -23.73K | -130.11 | 14.58 |
| EPS Diluted | -49.19 | 29.77 | 52.32 | -124.13 | -189.03 | -165.54 | -319.14 | -235.27 | -325.04 | -145.03 | -277.15 | -362.41 | -574.39 | -23.73K | -130.11 | 14.58 |
| Weighted Avg Shares Out | 39.90M | 39.05M | 38.31M | 32.95M | 23.15M | 16.63M | 12.46M | 9.83M | 8.10M | 7.69M | 5.79M | 4.78M | 3.66M | 27.06K | 1.67M | 1.44M |
| Weighted Avg Shares Out (Dil) | 39.90M | 39.61M | 38.84M | 32.95M | 23.15M | 16.63M | 12.46M | 9.83M | 8.10M | 7.69M | 5.79M | 4.78M | 3.66M | 27.06K | 1.67M | 1.44M |
Source: https://incomestatements.info
Category: Stock Reports